BA
NKTR icon

Boston Advisors’s Nektar Therapeutics NKTR Stock Holding History

Boston Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-553
Closed -$881K – 669
2018
Q1 		$881K Sell
553
-109
-16% -$140K 0.02% 388
2017
Q4 		$593K Sell
662
-636
-49% -$376K 0.01% 471
2017
Q3 		$467K Buy
+1,298
New +$406K 0.01% 505
2015
Q3 		– Sell
-1,586
Closed -$298K – 776
2015
Q2 		$298K Sell
1,586
-135
-8% -$23.2K 0.01% 597
2015
Q1 		$284K Buy
+1,721
New +$354K 0.01% 590

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Boston Advisors's NKTR Position: Q2 2018 in Review

Boston Advisors sold out of Nektar Therapeutics (NKTR) in Q2 2018, closing a stake of 553 shares — an estimated $881K sold.

Boston Advisors first reported a position in NKTR in Q1 2015 and held it in 5 quarters. The position peaked at $881K in Q1 2018. 378 funds tracked by Wall St. Rank hold NKTR as of Q2 2018.

  • Boston Advisors reported no remaining Nektar Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Boston Advisors sold 553 Nektar Therapeutics shares in Q2 2018, an estimated $881K.
  • Boston Advisors first reported a position in Nektar Therapeutics in Q1 2015 and held it in 5 quarters.
  • Boston Advisors's Nektar Therapeutics position peaked at $881K in Q1 2018.
  • 378 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2018.

Based on Boston Advisors's 13F filing for Q2 2018, filed 18 Jul 2018.